Genetic Testing for Hereditary Breast/Ovarian Cancer(BRCA1/2) CapitalBio

Clinical applications:

Preventive guidance - Detection of BRCA1/BRCA2 gene mutations can provide references for disease risk assessment to high-risk groups or healthy people, reduce the risk of disease through preventive treatment, and provide references for disease risk assessment to relatives of mutation carriers.

Medication guidance - Breast cancer and ovarian cancer patients with BRCA1/BRCA2 mutations are more sensitive to platinum and PARP inhibitor drugs (Olaparib), A large proportion of patients with BRCA1/ BRCA2 gene mutations are triple-negative breast cancers, which are more sensitive to platinum-based chemotherapy.

Prognostic assessment - BRCA1/BRCA2 gene mutation carriers have a relatively high risk of ipsilateral breast recurrence or contralateral breast cancer. BRCA1/BRCA2 gene mutations are relative contraindication to breast-conserving therapy.

Other Popular Searches From CapitalBio:

• 16s 18s its amplicon metagenomic sequencing

• Luxcan Technologies

• DNA microarray scanner

• how does a fully integrated data and analytics platform

• shotgun metagenomic service

• capital scanner

• fetal chrmoml aneuploidy

• HLA testing kit

• CNVSeq